Merck Sharp + Dohme Corp.

Schering Corporation

Intervet Inc.

Intervet International B.v.

Orchid Pharma Ltd.

Merch Sharp & Dohne Corp. Rahway

Michael W Miller

Duane E DeMong

Andrew William Stamford

Jack D Scott

Anandan Palani

Stuart W McCombie

Eric J Gilbert

Xing Dai

Kallol Basu

William J Greenlee

Bernard R Neustadt

John W Clader

Hubert B Josien

Susan F Vice

Brian Alexander McKittrick

Harry R Chobanian

Jayaram R Tagat

Bahige M Baroudy

Ruo Steensma

Barbara A Pio

Dong Xiao

Yan Guo

Mark A Laughlin

Elizabeth M Smith

Hong Liu

Christopher W Plummer

Marc A Labroli

Zhiyong Hu

Scott D Edmondson

Thomas J Greshock

Marc Poirier

Paul Tempest

Joel M Harris

Wei Li

Joseph A Kozlowski

Ravi P Nargund

John A McCauley

Steven L Colletti

Shuwen He

Ping Liu

Harold B Wood

Helen Y Chen

Wanying Sun

Jay Weinstein

De-Yi Yang

William Bert Geiss

Jinsong Hao

Zhiqiang Guo

Cangming Yang

Tze-Ming Chan

Wenqing Feng

Daniel Weston

John M Sanders

William K Hagmann

Wensheng Yu

Sheo B Singh

Brian J Lavey

Cheng Zhu

Gregori J Morriello

Bowei Wang

Milana M Maletic

Michael K C Wong

Shuzhi Dong

Rajan Anand

Guowei Zhou

Linda Brockunier

Liping Wang

Lehua Chang

Yuping Zhu

Anilkumar G Nair

Kevin D Dykstra

Vincent Colandrea

Ronald K Chang

Thomas A Bara

Katherine Young

Nam Fung Kar

Alejandro Crespo

Jason W Szewczyk

Joie Garfunkle

Kake Zhao

Hongwu Wang

Christopher R Moyes

Gopalan Balasubramanian

Heather E Stevenson

Kevin B Alton

Venkatesan Parameswaran

Yong Huang

Anima Ghosal

Swapan K Chowdhury

Kathleen M Cox

Karen M Marcantonio

Chander Shekher Celly

Maneesh Paul-Satyaseela

Jonathan T Kern

Hariharan Periasamy

Marc Poirer

Megan Macala

Chidambaram Venkateswaran Srinivasan

Sridhar Ramanathan Iyer

Sarah W Li

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia Formula (I). 

Antidiabetic bicyclic compounds

This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R, and Rare as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Substituted carbapenems for the treatment of bacterial infections

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia. 

Antidiabetic heterocyclic compounds

Antidiabetic spirochroman compounds

The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R9, and A are as defined herein, which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved. 

Compounds inhibiting leucine-rich repeat kinase enzyme activity

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

Antidiabetic compounds

The present invention is directed to substituted indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK2 kinase is involved.

The present invention is directed to indazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Growing community of inventors

Westfield, NJ, United States of America

Michael W Miller